Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Search Site

Over 2,750 Pages of
Hepatitis C Info, Here:
Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

UNITED STATES: FDA Approves Hepatitis B Viral DNA Test
The first hepatitis B virus (HBV) nucleic acid test to measure the amount of viral DNA in a patient's blood has won Food and Drug Administration approval. 'The COBAS TaqMan HBV Test extracts and then amplifies sections of viral DNA from human plasma or

Toll rises to 121 in Uganda hepatitis epidemic
A hepatitis E epidemic has killed 121 people in northern Uganda, where it erupted in October last year, a health ministry official said Thursday. A diagram showing the hepatitis C virus © AFP/File KAMPALA (AFP) - The outbreak has mainly affected

Roche Molecular Diagnostics Wins FDA OK for Hepatitis B Test
A hepatitis B viral load test, developed by Roche Molecular Diagnostics in Pleasanton, was approved by the Food and Drug Administration.

UPDATES AND COMMENTARY RSS Feed

HCV Genotype 1 Viral Loads Decline
A six-month follow-up to Intercell's Phase II trial of their Hepatitis C vaccine with a topical toll-like receptor agonist showed a significant reduction in viral load. While data from two weeks after the vaccination series showed promise, participants with Hepatitis...

Former Anti-Itch Drug Useful Against Hep C
California scientists have found that an old antihistamine drastically reduces Hepatitis C viral replication....

Hep C Treatment: Comparing the Pegylated Interferons
Learn about the facts on pegylated interferon alfa-2a and pegylated interferon alfa-2b, the standard treatment for chronic Hepatitis C. Comparing and contrasting the pegylated interferons may help better explain a physician’s preference or indifference between the two when treating their...

Slow Progression Rate of Fibrosis in Hepatitis C Virus Patients With Persistently Normal Alanine Transaminase Activity

table  2.   Histological and Virological Features
Normal ALT Group I (n = 102) Normal ALT HCV-RNA-Negative (n = 33) Normal ALT HCV-RNA-Positive (n = 66) Elevated ALT Group II (n = 102)
Liver biopsy (n) 67** 12 53 101
Activity score (mean ± SD) 0.60 ± 0.60* 0.25 ± 0.45dagger 0.70 ± 0.60 1.38 ± 0.70*
Median 1 (95% CI: 0-1)* 0 (95% CI: 0-1)dagger 1 (95% CI: 1-1) 1 (95% CI: 1-2)
Fibrosis score (mean ± SD) 0.95 ± 0.96 1.10 ± 1.10 0.90 ± 0.80 1.80 ± 1.10Dagger
Median 1 (95% CI: 0-1) 1 (95% CI: 0-1) 1 (95% CI: 1-1) 2 (CI: 1-2)Dagger
Fibrosis progression (mean ± SD) 0.07 ± 0.07 0.09 ± 0.07 0.07 ± 0.07 0.15 ± 0.11§
Median 0.05 (05% CI: 0.04-0.07) 0.08 (95% CI: 0-0.15) 0.05 (95% CI: 0.03-0.07) 0.13 (95% CI: 0.1-0.16)
Normal liver (A0-F0) 11/67 (16%) 2/12 (17%) 8/53 (15%)  4/101 (4%)parallel
Positive PCR 66/99 (66%) 33/33 (0%)  66/66 (100%) 82/85 (97%)
HCV viremiadagger dagger mean ± SD (range) 54.9 ± 132.7 (0-881) 0 68.4 ± 145.2 (2-881) 41.8 ± 62.6 (2-341)
Median 4.5 (95% CI: 3.5-21.4) 0 12.1 (95% CI: 4.2-31) 18.4 (95% CI: 13.6-28.7)
*  P < .0001 (between group I and the other groups).
dagger P = .01 between HCV-RNA-negative patients with normal ALT value and HCV-RNA-positive patients with normal ALT value.
Dagger P < .0001 (between group II and the other groups).
§  P < .0001 (between group II and the other groups).
parallel P < .01 (between group II and the other groups).
P < .0001 (between group I and II).
** In 2 patients, HCV RNA was not assessed; dagger dagger 105 Eqvir/mL.

Return To Article

table Of Contents

Copyright © 1998 by the American Association for the Study of Liver Diseases.
  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 07 Sep 2008